title: Dosage regimen of ranitidine in patients with renal impairment.
abstract: The validity of the Giusti-Hayton method for dosage regimen adjustment in patients with renal impairment was investigated using ranitidine. Five normal healthy volunteers received a single ranitidine recommended dose of 150 mg, and 20 patients with renal disease received single administration in doses individually calculated by the Giusti-Hayton method from each patient's creatinine clearance level, and the various pharmacokinetic parameters were compared. As a result, the area under the time-concentration curve 0----infinity (AUC0----infinity) in the renal disease patients was almost comparable to that in the normal healthy volunteers. The Giusti-Hayton method was considered useful to keep both the AUC0----infinity constant and the mean blood level of the drug in a steady state, in any degree of renal impairment.
authors.affiliation: Department of Clinical Pharmacology, Medical College of Oita, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Ebihara
authors.forename: K
authors.initials: K
authors.lastname: Ohashi
authors.forename: T
authors.initials: T
authors.lastname: Ikeda
authors.forename: M
authors.initials: M
authors.lastname: Yuhara
authors.forename: H
authors.initials: H
authors.lastname: Tagawa
authors.forename: M
authors.initials: M
authors.lastname: Yamakado
authors.forename: Y
authors.initials: Y
authors.lastname: Asano
authors.forename: K
authors.initials: K
authors.lastname: Tabei
authors.forename: K
authors.initials: K
authors.lastname: Nakazawa
authors.forename: K
authors.initials: K
authors.lastname: Kondo
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D002908:Chronic Disease; D003404:Creatinine / Q000378:metabolism*; D005260:Female; D005921:Glomerulonephritis / Q000503:physiopathology; D006801:Humans; D007262:Infusions, Intravenous; D007668:Kidney / Q000378:metabolism; D007674:Kidney Diseases / Q000378:metabolism*; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D009393:Nephritis / Q000503:physiopathology; D009404:Nephrotic Syndrome / Q000503:physiopathology; D011702:Pyelitis / Q000503:physiopathology; D011899:Ranitidine / Q000008:administration & dosage* / Q000493:pharmacokinetics; D013997:Time Factors
chemical_list: D011899:Ranitidine; D003404:Creatinine